| Literature DB >> 16504044 |
K-C Müller1, L Welker, K Paasch, B Feindt, V J Erpenbeck, J M Hohlfeld, N Krug, M Nakashima, D Branscheid, H Magnussen, R A Jörres, O Holz.
Abstract
BACKGROUND: The loss of alveolar walls is a hallmark of emphysema. As fibroblasts play an important role in the maintenance of alveolar structure, a change in fibroblast phenotype could be involved in the pathogenesis of this disease. In a previous study we found a reduced in vitro proliferation rate and number of population doublings of parenchymal lung fibroblasts from patients with emphysema and we hypothesized that these findings could be related to a premature cellular aging of these cells. In this study, we therefore compared cellular senescence markers and expression of respective genes between lung fibroblasts from patients with emphysema and control patients without COPD.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16504044 PMCID: PMC1435750 DOI: 10.1186/1465-9921-7-32
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Patients' characteristics (all patients, for data of subgroups see Results)
| Control | Emphysema | ||||
| n | 15 | 13 | |||
| Age | yr | 62 | (54; 67) | 64 | (58; 70) |
| Sex | m/f | 10/5 | 13/0 | ||
| BMI | kg/m2 | 24.9 | (24.3; 26.6) | 22.4 | (22.2; 23.9) * |
| VC | %pred | 101.7 | (87.2; 110.5) | 73.6 | (71.6; 90.0) ** |
| FEV1 | %pred | 94.7 | (83.9; 106.3) | 37.2 | (33.5; 40.7) ** |
| FEV1/VC | %pred | 99.0 | (94.3; 104.2) | 53.2 | (44.6; 54.0) ** |
| ITGV | %pred | 104.0 | (90.2; 117.8) | 181.0 | (167.0; 222.3) ** |
| RV | L | 2.12 | (1.86; 2.52) | 5.44 | (4.53; 6.42) ** |
| TLC | L | 6.47 | (4.60; 7.05) | 8.7 | (8.02; 9.89) ** |
| RV/TLC | % | 38.1 | (32.6; 45.1) | 64.1 | (54.1; 67.8) ** |
| Smoking history | packyears | 25 | (20;40) | 50 | (40;70) * |
| COPD stage | 0/I/II/III/VI | 15/0/0/0/0 | 0/0/1/11/1 | ||
| DT | h | 24.8 | (21.7; 25.5) | 31.2 | (29.3; 40.9) ** |
The table shows median values and quartiles (in parentheses), *p < 0.05, **p < 0.01 regarding the difference between groups. BMI = body mass index, VC = vital capacity, FEV1 = forced expiratory volume in one second, ITGV = intra thoracic gas volume, RV = residual volume, TLC = total lung capacity, DT = doubling time (time needed for doubling of cell number) of parenchymal lung fibroblasts in culture. Predicted values were taken form ERS guidelines [36] stages of COPD according to GOLD guidelines .
Primer sequences used for qPCR
| HUGO ID | 5'- sense primer- 3' | 5'- antisense primer – 3' | product (bp) | Sequence ID |
| PBGD [26] | CACACAGCCTACTTTCCAAGC | TTCAATGTTGCCACCACACT | 155 | NM_000190.2 |
| IGFBP-3 | CCTGCCGTAGAGAAATGGAA | GAAGGGCGACACTGCTTT | 127 | NM_000598 |
| IGFBP-5 | GAGCAAGTCAAGATCGAGAGAGA | GAAAGTCCCCGTCAACGTA | 463 | M65062 |
| IGFBP-rP1 | CTGCGAGCAAGGTCCTTCCATA | CAGGTTGTCCCGGTCACCA | 184 | NM_001553 |
| CTGF [22] | CCTGCAGGCTAGAGAAGCAGA | TGCACTTTTTGCCCTTCTTAATGT | 90 | NM_001901 |
| Cyr61 | ACACCAAGGGGCTGGAATG | TGGGGACACAGAGGAATG | 193 | AF31385 |
| LOXL2 | CGGAGGATGTCGGTGTGGT | GCTTGCGGTAGGTTGAGAGG | 150 | NM_002318 |
| OAZ1 | AGGTGGGCGAGGGAATAG | ATGCGTTTGGCGTCTGTG | 150 | U09202 |
| FOSL1 | CAGGCGGAGACTGACAAA | GGGAAAGGGAGATACAAGGT | 217 | NM_005438 |
| CDK4 | TGCAGTCCACATATGCAACAC | CAGCCCAATCAGGTCAAAG | 137 | M14505 |
Figure 1Distribution of the percentage of cells staining positive for SA-β-Gal in control patients and patients with emphysema in passage 4–5 (dotted line: median value).
Figure 2Southern blot of terminal telomere restriction fragments (derived from of Rsa I/Hinf I digestion of DNA samples) detected by chemiluminescence with a DIG-labeled telomeric probe in combination with anti-DIG-alkaline phosphatase (AP) secondary antibody and CDP-star-AP© substrate. Panel A: Samples from 8 control patients (2 separate gels with molecular weight markers). Panel B: Samples from 7 patients with emphysema (2 separate gels with molecular weight markers)
Figure 3Distribution of mean terminal telomere restriction fragment (TRF) lengths in control patients and patients with emphysema (dotted line: median value).
Results of gene expression analysis
| Target gene | cDNA array Emphysema/Control | qPCR Controls | qPCR Emphysema | p-value |
| IGFBP-3 | 1.3 | 0.38 (0.15; 0.40) | 0.82 (0.66; 1.36) | 0.024* |
| IGFBP-5 | 0.19 | 115.0 (60.5; 161.0) | 73.6 (49.0; 159.0) | 0.51 |
| IGFBP-rP1 (IGFBP-7) | 4.87 | 4.25 (2.67; 5.59) | 9.6 (6.77; 12.4) | 0.002** |
| IGFBP-rP2 (CTGF) | n.d. | 2.97 (1.68; 4.25) | 4.40 (3.86; 4.99) | 0.070 |
| IGFBP-rP4 (Cyr61) | 0.84 | 258 (222; 329) | 198 (185; 322) | 0.57 |
| LOXL2 | 3.88 | 1.27 (0.73; 1.79) | 1.41 (1.22; 1.92) | 0.63 |
| OAZ1 | 0.15 | 0.22 (0.17; 0.25) | 0.18 (0.18; 0.25) | 0.96 |
| FOSL1 | 0.21 | 0.89 (0.63; 1.16) | 1.00 (0.78; 1.34) | 0.57 |
| CDK4 | 0.16 | 0.91 (0.58; 1.18) | 0.73 (0.53; 0.78) | 0.63 |
The cDNA array column gives the differential gene expression in the exploratory 12 k array experiment as ratio of emphysema to control. qPCR columns give the gene expression of the target gene relative to PBGD for control patients and patients with emphysema. These values are the median values (IQR) of the normalized ratios as derived from RelQuant software. They were additionally corrected by using ratios of qPCR calibrators. P-values refer to the comparison of qPCR results between the two groups and were calculated by the Mann-Whitney U-test. *p < 0.05, **p < 0.01, n.d. not determined.
Figure 4Relative expression of target genes obtained by qPCR in control patients and patients with emphysema. Data points represent normalized ratios of gene expression relative to PBGD and corrected for qPCR calibrators (dotted line: median value). Values are expressed on a log-scale. Panel A: IGFBP-3 expression, Panel B: IGFBP-rP1 expression